GENENTECH, INC for GENENTECH INC
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Intellectual property and process patent issues Patent litigation reforms PTAB and IPR processes Section 101 Reform Domestic and international compulsory licensing issues March-in Rights
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
Health Issues HCR
Issues related to the 340B Drug Discount Program Issues relating to drug pricing Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. Issues related to healthcare legislation Patient access to Part B medicines during the COVID-19 public health emergency Issues related to health equity, diversity, and inclusion in clinical trials Issues related to advanced development and procurement of medical countermeasures (MCMs) Issues related to patient assistance and access Issues relating to privacy and securing the data of and personal information of consumers Issues relating to medical research data Issues relating to screening and diagnostics Issues related to public health preparedness and response Issues related to awareness about diabetic eye diseases in minority populations Issues related to public health preparedness. Issues related to access to drugs for minority communities Issues related to healthcare education and screening
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING | — |
| CALEB GRAFF | — |
| DAN NEVES | — |
| CHRISTIANA REASOR NULTY New | — |
| VALERIE REYNOLDS | — |
| ESTEVAN SANTANA New | — |
| JILL SHOTZBERGER | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Medicare/Medicaid MMM
Issues related to Medicare and Medicaid coverage and reimbursement Issues related to the 340B Drug Discount Program Issues related to drug pricing Medicare reimbursement for biosimilars Issues related to CMMI
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING | — |
| CALEB GRAFF New | — |
| DAN NEVES | — |
| VALERIE REYNOLDS | — |
| ESTEVAN SANTANA New | — |
| JILL SHOTZBERGER | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Taxation/Internal Revenue Code TAX
Issues related to R&D tax deductions and expense amortization Issues related to international taxation, including foreign-derived intangible income and interest deductions Issues related to supply chain incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Trade (domestic/foreign) TRD
Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver Issues related to compulsory licensing of foreign patents Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
Medical/Disease Research/Clinical Labs MED
Issues related to public health protection including influenza development and preparedness Issues related to antimicrobial and antiviral research and product development Issues related to novel coronavirus and COVID-19 research and product development Issues related to drug development including PDUFA and Cures 2.0
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING | — |
| DAN NEVES | — |
| JILL SHOTZBERGER | — |
Pharmacy PHA
Drug pricing issues Prescription Drug User Fee Act reauthorization Issues related to prescription drug value Issues related to the 340B Drug Discount Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING | — |
| JILL SHOTZBERGER | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Manufacturing MAN
Issues related to pharmaceutical supply chains Issues related to reporting on location of origin of pharmaceutical products Issues related to drug shortages Issues related to pharmaceutical manufacturing
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN NEVES | — |
| JILL SHOTZBERGER | — |
| THOMAS L. STOLL | — |
Immigration IMM
Issues relating to limits and restrictions on the immigration of high skilled workers Issues relating to the immigration of medical researchers
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
Budget/Appropriations BUD
Issues related to FDA and HHS program funding for the FY24 Labor, HHS, Education and Related Agencies, and FY24 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Strategic National Stockpile (SNS) Funding and Oversight Funding for FDA e-labeling rule implementation Patient access to Part B medicines during the COVID-19 public health emergency Issues related to 340B program oversight Support for increased investments to address antimicrobial resistance. Deficit reduction, reconciliation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAVID COOLING | — |
| CALEB GRAFF New | — |
| CHRISTIANA REASOR NULTY New | — |
| JILL SHOTZBERGER | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.